EryDel Overview

  • Founded
  • 2007
  • Status
  • Private
  • Employees
  • 22
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $32.7M
Latest Deal Amount
  • Investors
  • 5

EryDel General Information


Developer of a CE marked non-invasive device designed to facilitate blood processing at the point of care. The company's therapy is based on the unique properties of the erythrocytes to be reversibly opened under hypotonic conditions without losing their functionalities, enabling healthcare professionals and doctors to efficiently treat Ataxia Telangiectasia and other rare diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Drug Delivery
Other Pharmaceuticals and Biotechnology
Primary Office
  • Via Meucci 3
  • 20091 Bresso
  • Italy
+39 02 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

EryDel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 24-Apr-2018 $32.7M 000.00 Completed Generating Revenue
3. Grant 07-Jan-2016 00.000 0000 Completed Generating Revenue
2. Later Stage VC (Series B) 11-May-2015 $32.3M $36M Completed Generating Revenue
1. Early Stage VC (Series A) 03-Sep-2008 $3.7M $3.7M Completed Startup
To view EryDel’s complete valuation and funding history, request access »

EryDel Executive Team (7)

Name Title Board Seat Contact Info
Luca Benatti Ph.D Chief Executive Officer & Chairman
Giovanni Mambrini Ph.D Co-Founder & Chief Operating Officer
Mauro Magnani Co-Founder, Chief Scientific Officer & Board Member
Ronan Gannon Chief Commercial Officer
Guenter Janhofer MD Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

EryDel Board Members (13)

Name Representing Role Since
Carlo Incerti MD Self Chairman 000 0000
Claudio Giuliano Innogest Capital Board Member 000 0000
Federica Draghi Ph.D Self Board Member 000 0000
Francesca Pasinelli EryDel Board Member 000 0000
Graziano Seghezzi Sofinnova Partners Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

EryDel Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EryDel Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sofinnova Partners Venture Capital Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Genextra Venture Capital Minority 000 0000 000000 0
Focus Gestioni Venture Capital Minority 000 0000 000000 0
Innogest Capital Venture Capital Minority 000 0000 000000 0
To view EryDel’s complete investors history, request access »